公开(公告)号：US20230398214A1

公开(公告)日：2023-12-14

申请号：US17633294

申请日：2020-08-06

Applicant: Yeda Research and Development Co. Ltd. ,  Board of Regents, The University of Texas System

Inventor： Yair REISNER ,  Esther BACHAR-LUSTIG ,  Assaf LASK ,  Noga OR-GEVA ,  Rotem GIDRON BUDOVSKY ,  Rakefet SIDLIK MUSKATEL

IPC: A61K39/00 ,  C12N5/0783 ,  A61K31/664 ,  A61P37/06

CPC classification number: A61K39/4622 ,  C12N5/0636 ,  A61K39/4633 ,  A61K39/4614 ,  A61K39/464411 ,  A61K39/46444 ,  A61K39/464838 ,  A61K31/664 ,  A61P37/06 ,  A61K39/464429 ,  A61K39/4621 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2502/1121

Abstract: Methods of generating an isolated population of non-graft versus host disease (GVHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation, are disclosed. Cells generated by the methods, pharmaceutical compositions and methods of treatment are also disclosed.

公开(公告)号：US20230256028A1

公开(公告)日：2023-08-17

申请号：US18137449

申请日：2023-04-21

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Carmit HILLEL-KARNIEL ,  Chava ROSEN ,  Esther BACHAR-LUSTIG ,  Elias SHEZEN

IPC: A61K35/42 ,  A61P11/00 ,  A61K9/00 ,  A61K35/28

CPC classification number: A61K35/42 ,  A61P11/00 ,  A61K9/0019 ,  A61K35/28

Abstract: A method of treating a pulmonary disorder or injury in a subject in need thereof is disclosed. The method comprising administering to the subject non-syngeneic pulmonary tissue cells in suspension comprising an effective amount of hematopoietic precursor cells (HPCs) or supplemented with HPCs, wherein the effective amount is a sufficient amount to achieve tolerance to the pulmonary tissue cells in the absence of chronic immunosuppressive regimen. A method of inducing donor specific tolerance in a subject in need of a pulmonary cell or tissue transplantation is also disclosed.

公开(公告)号：US20190316087A1

公开(公告)日：2019-10-17

申请号：US16313486

申请日：2017-06-27

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Noga OR-GEVA ,  Rotem GIDRON BUDOVSKY ,  Esther BACHAR-LUSTIG ,  Assaf LASK ,  Sivan KAGAN

IPC: C12N5/0783 ,  C12N5/00 ,  A61K35/17 ,  A61K39/00

Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.

公开(公告)号：US20230039904A1

公开(公告)日：2023-02-09

申请号：US17958401

申请日：2022-10-02

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Esther BACHAR-LUSTIG

IPC: A61K35/28 ,  A61K31/675 ,  A61K35/22 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/407 ,  A61K35/42 ,  C12N5/00 ,  A61K31/198 ,  A61K31/255 ,  A61K31/7076 ,  A61P37/06 ,  A61P37/02 ,  A61K31/661 ,  A61K39/395

Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.

公开(公告)号：US20190328793A1

公开(公告)日：2019-10-31

申请号：US16508325

申请日：2019-07-11

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Esther BACHAR-LUSTIG

IPC: A61K35/28 ,  A61K35/38 ,  A61K31/198 ,  A61K31/255 ,  A61K39/395 ,  A61K31/661 ,  A61K35/42 ,  A61K35/407 ,  A61K35/39 ,  C12N5/00 ,  A61K35/36 ,  A61K35/34 ,  A61K35/22 ,  A61K31/675 ,  A61K31/7076

Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.

公开(公告)号：US20230383254A1

公开(公告)日：2023-11-30

申请号：US18232437

申请日：2023-08-10

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Noga OR-GEVA ,  Rotem GIDRON BUDOVSKY ,  Esther BACHAR-LUSTIG ,  Assaf LASK ,  Sivan KAGAN

IPC: C12N5/0783 ,  A61K35/17 ,  A61K39/00 ,  C12N5/00

CPC classification number: C12N5/0637 ,  A61K35/17 ,  A61K39/001 ,  C12N5/0087 ,  A61K2035/122

Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.

公开(公告)号：US20230321235A1

公开(公告)日：2023-10-12

申请号：US18020441

申请日：2021-08-11

Applicant: Yeda Research and Development Co. Ltd. ,  Ichilov Tech Ltd.

Inventor： Yair REISNER ,  Anat GLOBERSON LEVIN ,  Esther BACHAR-LUSTIG ,  Assaf LASK ,  Bar NATHANSOHN-LEVI ,  Tova WAKS ,  Galit HORN ,  Zelig ESHHAR

IPC: A61P35/00 ,  C12N5/0783 ,  A61K39/00

CPC classification number: A61K39/4611 ,  A61K39/4631 ,  A61P35/00 ,  C12N5/0636 ,  A61K2239/22 ,  C12N2510/00

Abstract: A method of generating a population of genetically modified veto cells is disclosed. The method comprising: (a) providing a population of cells comprising T cells, the T cells comprising at least 40% memory CD8+ T cells; (b) culturing the population of cells comprising T cells with an antigen or antigens under conditions which allow enrichment of tolerance-inducing antigen-specific cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being depleted of graft versus host (GVH) reactivity; and (c) transducing the cells with a polynucleotide encoding a heterologous cell surface receptor comprising a T cell receptor signaling module, thereby generating the population of genetically modified veto cells.

公开(公告)号：US20190338247A1

公开(公告)日：2019-11-07

申请号：US16478477

申请日：2018-01-18

Applicant: Yeda Research And Development Co. Ltd.

Inventor： Yair REISNER ,  Esther BACHAR-LUSTIG ,  Shlomit REICH-ZELIGER

IPC: C12N5/0783 ,  C07K14/725 ,  C12N5/00 ,  A61K35/17 ,  A61P35/04 ,  A61P35/00 ,  A61P35/02 ,  C07K16/32 ,  C07K16/30 ,  C07K16/28

Abstract: An isolated cytotoxic T-lymphocyte (CTL), said CTL being a tolerance inducing cell and substantially depleted of alloreactivity, and wherein said CTL does not comprise a central memory T-lymphocyte (Tcm) phenotype, the CTL being transduced to express a cell surface receptor comprising a T cell receptor signaling module, is disclosed. Methods of generating same and using same are also disclosed.

公开(公告)号：US20160354410A1

公开(公告)日：2016-12-08

申请号：US15242666

申请日：2016-08-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Assaf LASK ,  Eran OPHIR ,  Noga OR-GEVA ,  Adva COHEN ,  Ran AFIK ,  Esther BACHAR-LUSTIG ,  Yaki EIDELSTEIN

IPC: A61K35/17 ,  A61K35/28 ,  C12N5/0783 ,  A61K45/06

CPC classification number: A61K35/17 ,  A61K31/517 ,  A61K35/28 ,  A61K39/001 ,  A61K45/06 ,  A61K2035/124 ,  A61K2039/5158 ,  C12N5/0602 ,  C12N5/0636 ,  C12N5/0637 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  A61K2300/00

Abstract: A method of treating a disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting a non-syngeneic cell or tissue graft to the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of cells comprising non-graft versus host (GVHD) inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, and further wherein the cells are either: (i) non-syngeneic with both the subject and the graft; or (ii) non-syngeneic with the graft and syngeneic with the subject, thereby treating the subject.

公开(公告)号：US20230024587A1

公开(公告)日：2023-01-26

申请号：US17735146

申请日：2022-05-03

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Yaki EIDELSTEIN ,  Eran OPHIR ,  Assaf LASK ,  Ran AFIK ,  Noga OR-GEVA ,  Esther BACHAR-LUSTIG

IPC: A61K35/17 ,  A61K39/00 ,  C12N5/0783 ,  A61K35/22 ,  A61K35/26 ,  A61K35/28 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/407 ,  A61K35/42

Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.